Approval of unaudited financial result (Standalone) for quarter ended june 30, 2026.

AUGUST 10, 2026 Department of Corporate Affairs- Listing BSE Limited PhirozJeeJeebhoy Towers, Dalal Street, Fort Mumbai-400001 Scrip Code: 530313 [KIMIABL], ISIN: INE285U01025 Sub: Outcome of Board Meeting held on August 10, 2026 (Monday) Dear Sir, Pursuant to Regulation 33 and 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we have enclosed herewith: 1. Unaudited Financial Results for the First quarter ended June 30, 2026, duly approved and taken on record by the Board of Directors at its meeting held today i.e. Monday, August 10, 2026. 2. Limited Review Report on the aforesaid results from Statutory Auditors of the Company, as placed before the Board of Directors of the Company in its meeting held today. The Board Meeting commenced at 04:00 p.m. and concluded at 04:30 p.m. Kindly take the above information on your records. Thanking You, Yours faithfully, For KIMIA BIOSCIENCES LIMITED ABHISHEK PANDEY COMPANY SECRETARY AND COMPLIANCE OFFICER M. NO F12457 PLACE: GURUGRAM Encl.: a/a compliance.kimiabiosciences@gmail.com | info@kimiabiosciences.com | www.kimiabiosciences.com | CIN No.:L24239HR1993PLC032120 KIMIA BIOSCIENCES LIMITED Regd. Office : Village Bhondsl, Tehsll Sohnn, Dist. Gurgaon, larynnn - 122102 A. Phone +91 9654746544, 9654206544 Email: compliance.kimiabiosciences@gmail.com & info@kimiabiosciences com Website www.kimiabiosciences com, CIN : L24239HR1993PLC032120 UNAUDITED FINANCIAL RESULTS (STANDALONE) FOR TIE QUARTER ENDED JUNE 30, 2026 ( Lnkhs except EPS) S. No. Particulars Quarter ended Yenr Ended 30-Jun-26 31-Mar-26 30-Jun-25 31-Mar-26 (Unaudited) (Audited) (Unaudited) (Audited) I [Revenue from Operations 2,072.25 2,719.98 2,358.41 11,488. 38 II Other Income 8.06 100.69 84,69 16217 II Total Income (I+II) 2,080.3J 2,820.67 2,443.10 11,650.55 IV Expenses: a) Cost of materials consumed 1,656.68 1,381.03 1,706.19 6,565.79 b) Change in inventories of finished goods and work-in-progress (533.54) 322.26 (290.32) 446.09 c) Employee benefits expenses 296 97 303.87 327.67 1,261.61 d) Finance costs 83.05 75.30 174,71 351.57 391.32 e) Depreciation and amortisation expense 110,74 115.51 93.53 D) Other expenses 417.43 446.26 362.18 1,788.16 V 'Total Expenses(IV) 2,031.33 2,644.23 2,373.96 10,804.54 VI 'Profit/(loss) before exceptional items and Tar (II-V) 48.98 176.44 69.14 846.01 VII 'Exceptional Items VI 'Profit/(loss) before tax (IV-V) 48.98 176.44 69.14 846.01 VI] 'Tax expenses: . a) Current Tax . . b) Current Tax related to earlier years b) Deferred Tax charge / (credit) 13.40 140.68 8.74 104.19 VIII 'Profit/(loss) for the period (VI-VII) 35.58 35.76 60.40 741.82 LX [Other Comprehensive Income A. 'Items that will not be reclassified to Profit or Loss (Net of Tax) - Remeasurement of defined benefit plans . 0 42.85 42.85 B Items that will be reclassified to Profit or Loss (Net of Tax) (10.78) (10.78) X 'Total Comprehensive Income for the period (VIII+IX) 35.58 67.83 60.40 773.89 XI [Paid up equity share capital (Face value of Rs.I per equity share) 473.13 473.13 47313 473.13 XII [Other Equity XIII 'Earnings per equity share (not annualised) Basic in Rs. 0.08 0.14 0.13 1.64 Diluted in Rs 0.08 0.14 0.13 1.64 Other Notes 1 'The business activity of the Company falls within a single primary business segment viz 'Pharmaceuticals' and hence there is no other reportable segment as per Ind AS 108 'operating segments'. 2 The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on Auaust 10, 2026. Place: Gurugram -1LeerGoel Date: August 10, 2026 Managing Director and CEO DIN - 00161786 (rT) Neeraj Arora & Associates CA Neeraj Kumar Arora M: +91 9911099977 UY?) chartered Accountants E: neerajaroraassociates@gmail.com Review Report The Board of Directors Kimia Biosciences Limited Village Bhondsi, Tehsil Sohna Gurgaon Haryana-122102 I. We have reviewed the accompanying statement of unaudited financial results of Kimia Biosciences Limited (the "Company") for the quarter ended June 30, 2026 and year to date results for the period from April O I, 2026 to June 30, 2026 (the "Statement"), being submitted by the company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulation, 2015"), which has been initialled by us for identification purposes. 2. The statement is the responsibility of the Company's Management which has been approved by the Board of Directors and prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review. 3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, " Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion. 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in accordance with applicable accounting standards prescribed under Section 133 of the Companies Act 2013 and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement. For Neeraj Arora and Associates FRN 021309 Neeraj Kumar Arora M. No. 510750 UDIN:- 26510750TVWRLQ7279 Place:- Faridabad Dated:- August I 0, 2026 lecwEA ea o Au